TD Cowen Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its target price lowered by TD Cowen from $132.00 to $122.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. TD Cowen’s price objective points to a potential upside of 10.28% from the company’s previous close.

Several other research firms have also weighed in on BNTX. HSBC increased their target price on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Bank of America raised their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, UBS Group boosted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Five analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $134.69.

BioNTech Price Performance

NASDAQ BNTX traded up $1.66 on Tuesday, hitting $110.63. 200,977 shares of the company were exchanged, compared to its average volume of 781,077. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The firm has a 50 day moving average of $110.15 and a two-hundred day moving average of $96.06. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The company has a market cap of $26.30 billion, a P/E ratio of -48.95 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 EPS. On average, equities analysts predict that BioNTech will post -2.93 EPS for the current year.

Institutional Trading of BioNTech

Several hedge funds have recently added to or reduced their stakes in the company. Covestor Ltd boosted its holdings in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. GAMMA Investing LLC increased its position in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the period. EverSource Wealth Advisors LLC raised its stake in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares in the last quarter. Blue Trust Inc. lifted its position in BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares during the period. Finally, Crewe Advisors LLC acquired a new stake in BioNTech during the first quarter worth about $75,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.